Anti-Brain Cancer Compound Library

Description: Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.
MCE designs a unique collection of 1,518 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

Advantages:

• A unique collection of 1,518 compounds with definite or potential anti-brain cancer activity for high throughput screening (HTS) and high content screening (HCS).
• The compound library targets include PD-1, PKC, MEK,CDK etc.
• A useful tool for the discovery of compounds for brain cancer.
• Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
• Structurally diverse, bioactive, and cell permeable.
• More detailed compound information with structure, IC50, and other chemical & biological data.
• High purity and quality validated by NMR and LC/MS.
• All compounds are in stock and continuously updated.

Formulation: A collection of 1,518 anti-brain cancer compounds supplied as pre-dissolved Solutions or Solid.Solution:1,477 compounds supplied in 10 mM solution,38 compounds supplied in 2 mM solution,3 compounds supplied in 3 mg/mL solution.

Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.

Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

• Artikelnummer: MEXHY-L188-30
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-L188-30
• Verpackungseinheit: 30 µl
• Mengeneinheit: STK